




Molecular Cell, Volume 61


Supplemental Information

Releasing Activity Disengages Cohesin's Smc3/Sccl

Interface in a Process Blocked by Acetylation


Frederic Beckouët, Madhusudhan Srinivasan, Maurici Brunet Roig, Kok-Lung Chan, Johanna C. Scheinost, Paul Batty, Bin Hu, Naomi Petela, Thomas Gligoris, Alexandra C. Smith, Lana Strmecki, Benjamin D. Rowland, and Kim Nasmyth

A**B**









B

<i>WT</i>	<i>waplΔ</i> <i>eco1Δ</i>
<i>K404E</i> <i>eco1Δ</i>	<i>7A</i> <i>eco1Δ</i>



YPD 30C





Supplementary Figure Legends

Figure S1. Related to Figures 1 and 2

(A) Stability of Scc1 cleavage fragments in releasing activity mutants. Wild type (K17960), *wpl1* Δ (K20236) and *pds5-S81R* (K20521) strains expressing *CDC20* from the *GAL* promoter were grown to logarithmic phase at 25⁰C in YP medium containing galactose, transferred to galactose free media to induce metaphase arrest (time 0), and anaphase triggered by galactose re-addition. Separase cleavage of Scc1 was followed by Western blotting, C-terminal HA epitopes.

(B) Wapl triggers dissociation of NScc1 from Smc3 HOS1 or *hos1* Δ strains containing galactose inducible *WPL1* gene, K22555 (*MATa SMC3 (S1043C)-HA6 MYC3-SCC1(TEV268) pGAL1-10-WPL1*) and K22810 (*MATa hos1 Δ SMC3(S1043C)-HA6 MYC3-SCC1(TEV268) pGAL1-10-WPL1*) were grown in YP Raffinose medium at 25⁰C and were arrested in nocodazole for 2 hours. Galactose was then added to induce Wapl expression. Samples were taken at the indicated time points to immunoprecipitate Smc3 and analysed by Western blotting using anti MYC antibodies. The structure of Smc3-Scc1NTD complex PDB:4UX3 is shown with Scc1 C56, Smc3 S1043 residues marked.

Figure S2. Related to Figure 4. Scc3's highly conserved surface is essential for release

(A) Surface conservation of Scc3 orthologs projected on the surface of Zr *Scc3* (blue most and red least conserved) highlighting the conserved K364, Y371, K372, T401, K404, W408 and R449 (*S. cerevisiae*) surface residues that were mutated (7A). **(B)** A YPD plate with Strain K699 (W3031a), K16432 (*eco1* Δ *wpl1* Δ), K23905 (*eco1* Δ *scc3 K404E*) and K23908 (*eco1* Δ *scc3 7A*) grown at 30⁰C shows the suppression of *eco1* Δ by *scc3 (K404E and 7A)* mutants. **(C)** Shows live cell imaging of strains K23851 (*WPL1-eGFP MTW1-RFP*), K23854 (*WPL1-eGFP MTW1-RFP scc3 K404E*) and K23852 (*WPL1-eGFP MTW1-RFP scc3 7A*) that were grown to exponential phase in YPD at 25⁰C. GFP (Wapl) RFP (Mtw1) and DIC channels are shown.

Figure S3. Related Figure 5. Role of residues within Scc1's NTD in the release mechanism

(A) YPD plates with Strain K699 (W3031a), K24507 (*SCC1-HA eco1-1(G211D)*), and K24514 (*SCC1 MI02K-HA eco1-1(G211D)*) were grown at 25⁰C, 30⁰C and 37⁰C. (B) Diploid (*MATa/α SMC3 smc3Δ TRP1::smc3 K112R K113R Eco1 eco1Δ scc1Δ SCC1 MI02K*) was sporulated, tetrads dissected, and selected haploid segregants with their genotypes shown. (C) Exponentially growing strains K699 (W3031a), K20307 (*SCC1-HA eco1-1*), K20311 (*SCC1MI02K-HA eco1-1*), K16300 (*eco1-1*), K18879 (*SCC1-HA*) and K18881 (*SCC1MI02K-HA*), grown at either permissive 25⁰C or the non permissive 37⁰C were lysed and the levels of Smc3 acetylation (Smc3-AC) was detected using antibody that recognises Smc3 K112 K113 AC. Scc1 levels was measured using anti HA antibody and Swi6 was used as loading control. The data are from the same western blot with irrelevant lanes removed.

Figure S4. Related to Figure 5 and 7

(A) Role of residues within Smc3's ATPase domain in release

Diploids (*MATa/α scc1Δ LEU2::MYC-SCC1 TRP1::smc3 K112R K113R D1189H eco1Δ wpl1Δ*) was sporulated, tetrads dissected, and selected haploid segregants with their genotypes shown.

(B) Disengagement of NScc1 from Smc3 requires a single round of ATP hydrolysis

Strains K23567 (*MATa SMC3 URA3::SMC3 S1043C-HA6 MYC3-SCC1(TEV268) pGAL1-10-WPL1*) and K23566 (*MATa SMC3 URA3::smc3(S1043C E1155Q-HA6 MYC3-SCC1(TEV268), pGAL1-10-WAPL*) were grown in YP Raffinose medium at 25⁰C and were arrested in nocodazole for 2 hours. Galactose was then added to induce Wapl expression. Samples were taken at the indicated time points to induce *in vivo* cross-linking with 5mM BMOE. Cross-linking was analysed by Western blotting using anti HA antibodies.

(C) Disengagement of NScc1 from Smc3 involves engagement of Smc ATPase heads

Exponentially growing strains K24297 (*MATa SMC3 S1043C::ADE2 MYC3-SCC1(TEV268) SMC1*), K24523 (*MATa SMC3 S1043C::ADE2 MYC3-SCC1(TEV268) smc1 L1129V*) and K24521 (*MATa SMC3 S1043C::ADE2 MYC3-*

SCC1(TEV268) smc1 D1164E were treated as described in Figure 6(C) and analysed by western blotting using anti MYC antibodies. The positions of the Smc1 L1129 and D1164 residues are marked in a model of Smc1 and Smc3 head domains that are in an engaged state.

Strain construction

The 7A mutant version of *scc3* (under its native promoter) was incorporated at the *leu2* locus in heterozygous *SCC3/scc3Δ* diploids cells. Diploids were sporulated and tetrads dissected at 23 °C on YPD plates. The genotype of the resulting haploids was determined by replica plating, and viable cells with only the ectopic copy were used in this manuscript. The single mutants K404E, K404A, Y405E and Y405A on *scc3* were generated modifying the genome in *S.cerevisiae* using the CRISPR-Cas9 systems. For this we co-transformed the cells with a 600nt PCR “healing fragment” along with a 2 micron *LEU2* plasmid constitutively expressing Cas9 endonuclease and transcribing the structural RNA that contains the Cas9 binding site and the guide RNA that will target the double strand break formation by Cas9 to the *scc3* gene. The guide RNA was designed 20nt upstream of the NGG (L455, E456) using the annealed oligos MB530F/MB530R (MB530F: 5’-ATCACGCTTCAAACTAAGATCC-3’ , MB531R: 5’- AACGGATCTTAGTTTTGAAGCGT-3’) and fused afterwards at the 5’ end of the structural RNA with a Sap1 cloning. The 600nt PCR “healing fragment” containing the single mutants, a mutagenized NGG Cas9 sequence target (L455, E456: CTGGAA to CTAGAA) and 5’-, 3’- homology arms by which to repair the double strand break created by Cas9 was created using the oligos MB528F/MB529R (MB528F: 5-CTTGTGTTGGATTTGTTGAC-3’, MB529R: 5’-TGGATACTGTGGATCCTTACATCAAGATTAACGTCACGGATTGCCACTTCTAGGATCTTAGTTTTGAAGCG-3’). As a control, no colonies were obtained after yeast transformation of the 2 micron *Leu2* plasmid alone without the “healing fragment”. All mutations were confirmed afterwards by genome sequencing.

In vivo chemical cross-linking

Strains were grown in YEPD at 25 °C to $OD_{600nm} = 0.5-0.6$ and arrested in nocodazole for 1.5 h. 30 OD units were washed in ice-cold PBS, then re-suspended in 1.5 ml ice-cold PBS. The suspensions were then split into 2 x 750 μ l and 35 μ l BMOE (stock: 125 mM in DMSO, 5 mM final) or DMSO was added for 6 min on ice. Cells were washed with 2 x 2 ml ice-cold PBS containing 5 mM DTT, resuspended in 500 μ l EBX lysis buffer containing 1 mM DTT, benzonase (1:1000), RNase (0.1 mg/ml), Roche Complete Protease Inhibitors (2X) and PMSF (1 mM), lysed in a FastPrep-24 (MP Biomedicals) for 3 min at 6 m/s with 500 μ l of acid-washed glass beads (425-

600 μ m, Sigma) and lysates cleared (5 min, 12 kg). Protein concentrations were adjusted after Bradford assay and cohesin immuno-precipitated using anti-PK antibody (AbD Serotec, 1 h, 4 °C), anti MYC antibody (Santa cruz 1 h, 4 °C), and protein G dynabeads (1 h, 4 °C with rotation) or Anti HA affinity resin (Roche, 1 h, 4 °C). Beads were washed with 2 x 1 ml lysis buffer, resuspended in 50 μ l 2x sample buffer, incubated at 65°C for 5 min and the supernatant loaded onto a either 3-8% or 4-12% gradient gels (life technologies).

Mini Chromosome IPs

Strains containing a 2.3KB minichromosome were grown in YEPD at 25 °C and processed for in vivo crosslinking like mentioned above. For Southern blotting, pull-downs of lysates (in 25 mM Hepes pH 8.0, 50 mM KCl, 50 mM MgSO₄, 10 mM trisodium citrate, 25 mM sodium sulfite, 0.25% triton-X, Roche Protease Inhibitor, 1 mM PMSF, 2 mM DTT, 0.1 mg/ml RNase) containing a circular 2.3 kb minichromosome were performed as above, DNA was eluted in 30 μ l 1% SDS with DNA loading dye (65 °C, 4 min) and run on 0.8% agarose gels containing ethidium bromide (1.4 V/cm, 22h, 4 °C).

Protein Purification

E. coli BL21(DE3) RIPL cells (Stratagene) were transformed with pET vectors containing the *S. cerevisiae* Scc3 WT, Scc3 E404K and Wapl genes and induced at OD₆₀₀ 0.6 with 1 mM IPTG at 23 °C over night. The cells were pelleted and re-suspended with TAP buffer (50 mM Tris-HCl, 250 mM NaCl, 1 mM β -mercaptoethanol, pH 7.5) adding EDTA-free protease inhibitor cocktail tablets (Roche). After re-suspension, and one round of cell lysis at 18 KPsi (Constant Systems), 1 min sonication at 80% AMPL (Sonics Vibra-Cell) were performed. Cell lysate was pre-cleared by centrifugation at 4000 rpm for 15 min, and supernatant was cleared by centrifugation at 15,000 rpm for 1 h at 4 °C (Beckman Coulter, rotor JLA-16.250). All purified proteins are His₆ tagged and supernatants were incubated with Talon Superflow beads (Clontech) for 3 h at 4 °C. Beads were washed 3 times with TAP buffer containing 10 mM imidazole. Proteins were eluted in TAP buffer with 500 mM imidazole and loaded onto a Superdex 200 16/60 chromatography column

(GE Healthcare) equilibrated with TAP buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM β -mercaptoethanol, pH 7.5). Peak fractions were collected and concentrated using Vivaspin columns (Sartorius Stedim Biotech).

Gel filtration for Protein Binding

For in vitro binding assays, 15 μ M of each pure protein were incubated at 4 °C for 2–3 h, at a final volume of 150 μ l in TAP buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM β -mercaptoethanol, pH 7.5) and then loaded onto a Superose 6 (GE Healthcare) column. 15 μ l protein fractions were collected and analyzed by 3-8% SDS-PAGE and Coomassie staining.